2 withdrawn, 1 recruiting. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Withdrawn 2, Recruiting 1 |
Follow pibrentasvir: new trials by email Literature Review of pibrentasvir trials Research Report on pibrentasvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] - End Stage Renal Disease, Chronic Hepatitis c | Phase 4 | Withdrawn | Massachusetts General Hospital | 2020-11-13 | 2022-03-08 | |
| Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir Sofosbuvir 400mg [Sovaldi], Glecaprevir/pibrentasvir (300mg/120mg) - Hepatitis C | Phase 4 | Recruiting | Kirby Institute | 30 | 2020-02-11 | 2026-07-29 |
| Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant glecaprevir/pibrentasvir tablets - Kidney Failure, Kidney Diseases | Phase 4 | Withdrawn | Raymond T. Chung, MD | 2019-02-15 | 2019-06-03 |
Hepatitis C (3) · Hepatitis C, Chronic (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Renal Insufficiency (1)
Kirby Institute (1) · Massachusetts General Hospital (1) · Raymond T. Chung, MD (1)
United States (2) · Australia (1)